Vertex’s Islet Cell Therapy VX-880 Restores Endogenous Insulin Secretion in Type 1 Diabetes
Vertex Pharmaceuticals’ VX-880, an investigational allogeneic insulin-producing islet cell therapy, has restored endogenous insulin secretion in patients with type 1 diabetes (T1D) treated in the phase 1/2 FORWARD clinical trial (NCT04786262).1 The data were announced in an oral presentation at the 85th Scientific Sessions of the American Diabetes Association® (ADA) , held June 20 to 23, in Chicago, IL, and simultaneously reported in the New England Journal of Medicine.
Among 12 patients with T1D with impaired hypoglycemic awareness treated in FORWARD, all 12 showed restored endogenous insulin secretion, as assessed via C-peptide. Furthermore, the patients showed cessation of severe hypoglycemia events and hit recommended glycemic control targets, which constituted A1C at less than 7% and time in range of greater than 70%. Use of exogenous insulin was cut down by a mean of 92% across all patients, with 10 of the 12 patients no longer using exogenous insulin at all.
With regard to safety, adverse events (AEs) were noted to be in line with expectations for islet infusion procedures and the immunosuppressive drug regimens. There were no other AEs seen in the treated patients.
Click on the link for the full article
A good start. Let's see what the results are in Phase 3 trials.
